Skip to content

Study · Randomized controlled trial · n = 31 · 2022

6 results

Liraglutide for Weight Management in Children and Adolescents With Prader-Willi Syndrome and Obesity.

Diene G, Angulo M, Hale PM, Jepsen CH, Hofman PL, Hokken-Koelega A, Ramesh C, Turan S, Tauber M

The Journal of clinical endocrinology and metabolism1 Dec 2022Cited by 47 (Europe PMC)

PMID36181471 (opens in a new tab)PMCIDPMC9759167 (opens in a new tab)DOI10.1210/clinem/dgac549 (opens in a new tab)PepBankPUB-36181471
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adolescents with Prader-Willi syndrome and obesity, the change in BMI SDS with liraglutide did not differ significantly from placebo/no treatment at weeks 16 and 52.

    In plain wordsIn adolescents with Prader-Willi syndrome, liraglutide did not change BMI score more than placebo or no treatment.

    Peptide
    Liraglutide
    Outcome
    No significant changeBMI SDS change at weeks 16 and 52, adolescents
    Study

    n = 31

    Comparator
    Placebo/no treatment
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg (or maximum-tolerated dose) · 52 weeksAs given in this study (human).

    Measurements

    Estimated treatment difference, BMI SDS week 16
    −0.07 SDS
    adolescents
    Estimated treatment difference, BMI SDS week 52
    −0.14 SDS
    adolescents

    Source sentences

    Summary
    Change in BMI SDS from baseline to weeks 16 and 52 was not significantly different between treatments in adolescents (estimated treatment difference: -0.07 at week 16 and -0.14 at week 52) and children (-0.06 and -0.07, respectively).
    2 context sentences
    Summary · context
    Adolescents (n = 31, aged 12-17 years; Tanner stage 2-5) and children (n = 24, aged 6-11 years; Tanner stage <2) with PWS and obesity were included.
    Summary · context
    Patients were randomized 2:1 to liraglutide 3.0 mg (or maximum-tolerated dose) or placebo for 16 weeks, after which placebo was stopped.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In children with Prader-Willi syndrome and obesity, the change in BMI SDS with liraglutide did not differ significantly from placebo/no treatment at weeks 16 and 52.

    In plain wordsIn children with Prader-Willi syndrome, liraglutide did not change BMI score more than placebo or no treatment.

    Peptide
    Liraglutide
    Outcome
    No significant changeBMI SDS change at weeks 16 and 52, children
    Study

    n = 24

    Comparator
    Placebo/no treatment
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg (or maximum-tolerated dose) · 52 weeksAs given in this study (human).

    Measurements

    Estimated treatment difference, BMI SDS week 16
    −0.06 SDS
    children
    Estimated treatment difference, BMI SDS week 52
    −0.07 SDS
    children

    Source sentences

    Summary
    Change in BMI SDS from baseline to weeks 16 and 52 was not significantly different between treatments in adolescents (estimated treatment difference: -0.07 at week 16 and -0.14 at week 52) and children (-0.06 and -0.07, respectively).
    2 context sentences
    Summary · context
    Adolescents (n = 31, aged 12-17 years; Tanner stage 2-5) and children (n = 24, aged 6-11 years; Tanner stage <2) with PWS and obesity were included.
    Summary · context
    Patients were randomized 2:1 to liraglutide 3.0 mg (or maximum-tolerated dose) or placebo for 16 weeks, after which placebo was stopped.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adolescents with Prader-Willi syndrome and obesity, the hyperphagia total score at week 52 was lower with liraglutide than with no treatment.

    In plain wordsIn adolescents with Prader-Willi syndrome, overall hunger scores were lower with liraglutide than with no treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseHyperphagia total score at week 52, adolescents
    Study

    n = 31

    Comparator
    Placebo/no treatment
    Analysis
    Secondary
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    3.0 mg (or maximum-tolerated dose) · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    At week 52, hyperphagia total and drive scores were lower in adolescents treated with liraglutide vs no treatment.
    2 context sentences
    Summary · context
    Adolescents (n = 31, aged 12-17 years; Tanner stage 2-5) and children (n = 24, aged 6-11 years; Tanner stage <2) with PWS and obesity were included.
    Summary · context
    Patients were randomized 2:1 to liraglutide 3.0 mg (or maximum-tolerated dose) or placebo for 16 weeks, after which placebo was stopped.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adolescents with Prader-Willi syndrome and obesity, the hyperphagia drive score at week 52 was lower with liraglutide than with no treatment.

    In plain wordsIn adolescents with Prader-Willi syndrome, hunger drive scores were lower with liraglutide than with no treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseHyperphagia drive score at week 52, adolescents
    Study

    n = 31

    Comparator
    Placebo/no treatment
    Analysis
    Secondary
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    3.0 mg (or maximum-tolerated dose) · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    At week 52, hyperphagia total and drive scores were lower in adolescents treated with liraglutide vs no treatment.
    2 context sentences
    Summary · context
    Adolescents (n = 31, aged 12-17 years; Tanner stage 2-5) and children (n = 24, aged 6-11 years; Tanner stage <2) with PWS and obesity were included.
    Summary · context
    Patients were randomized 2:1 to liraglutide 3.0 mg (or maximum-tolerated dose) or placebo for 16 weeks, after which placebo was stopped.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In children and adolescents with Prader-Willi syndrome and obesity, changes in other weight-related parameters did not differ significantly between liraglutide and placebo/no treatment.

    In plain wordsIn young people with Prader-Willi syndrome, other weight measures did not change more with liraglutide than with placebo or no treatment.

    Peptide
    Liraglutide
    Outcome
    No significant changeOther weight-related parameters
    Study

    n: not reported in source

    Comparator
    Placebo/no treatment
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg (or maximum-tolerated dose) · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Changes in other weight-related parameters between treatments were not significant.
    2 context sentences
    Summary · context
    Adolescents (n = 31, aged 12-17 years; Tanner stage 2-5) and children (n = 24, aged 6-11 years; Tanner stage <2) with PWS and obesity were included.
    Summary · context
    Patients were randomized 2:1 to liraglutide 3.0 mg (or maximum-tolerated dose) or placebo for 16 weeks, after which placebo was stopped.
  6. 06HumanRandomized controlled trialSafety outcome

    In children and adolescents with Prader-Willi syndrome and obesity, the most common adverse events with liraglutide were gastrointestinal disorders.

    In plain wordsIn young people with Prader-Willi syndrome, the most common side effects of liraglutide were stomach and bowel problems.

    Peptide
    Liraglutide
    Outcome
    Not applicableMost common adverse events
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    3.0 mg (or maximum-tolerated dose) · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    The most common adverse events with liraglutide were gastrointestinal disorders.
    2 context sentences
    Summary · context
    Adolescents (n = 31, aged 12-17 years; Tanner stage 2-5) and children (n = 24, aged 6-11 years; Tanner stage <2) with PWS and obesity were included.
    Summary · context
    Patients were randomized 2:1 to liraglutide 3.0 mg (or maximum-tolerated dose) or placebo for 16 weeks, after which placebo was stopped.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02527200

Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome

Novo Nordisk A/Sn = 569 Nov 2015 to 19 Nov 2020

Metabolism and Nutrition Disorder · Obesity

Trial pageClinicalTrials.govUpdated 6 Jul 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.